Stockscreener 앱 받기
23.15
4.37%
0.97
시장 영업 전:
22.80
-0.35
-1.51%
전일 마감가:
$22.18
열려 있는:
$22.41
하루 거래량:
958.18K
Relative Volume:
1.18
시가총액:
$2.00B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-10.57
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
+1.80%
1개월 성능:
-9.61%
6개월 성능:
-43.38%
1년 성능:
-43.58%
1일 변동 폭
$22.22
$23.30
1주일 범위
$22.10
$24.05
52주 변동 폭
$22.10
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
23.15 | 2.00B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
BTIG reiterates Buy on Ideaya stock, cites significant updates - MSN
BTIG reiterates Buy on Ideaya stock, cites significant updates By Investing.com - Investing.com Canada
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Has $2.53 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya stock touches 52-week low at $22.15 amid market challenges - MSN
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expands By 10.1% - MarketBeat
IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowHere's Why - MarketBeat
IDEAYA Biosciences’ (IDYA) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Ideaya stock touches 52-week low at $22.15 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partners Downgrades IDEAYA Biosciences (IDYA) - MSN
Learn to Evaluate (IDYA) using the Charts - Stock Traders Daily
Royal Bank of Canada Reaffirms "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - Marketscreener.com
IDEAYA Biosciences Unveils Ambitious 2025 Growth Plan, $1.2B Cash Position Funds Through 2028 - StockTitan
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month Low – Here’s Why - Defense World
Why IDEAYA Biosciences Stocks Are Gaining Attention - TipRanks
Ideaya Biosciences stock hits 52-week low at $24.14 By Investing.com - Investing.com Australia
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.14 - Investing.com
Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $53.67 - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks - Investing.com Australia
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Sells 4,968 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
IDEAYA Biosciences in-licenses Hengrui’s SHR-4849 - The Pharma Letter
Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld Online
IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma - Defense World
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - Kilgore News Herald
Ideaya Biosciences stock hits 52-week low at $24.38 By Investing.com - Investing.com Nigeria
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month LowHere's Why - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.38 - Investing.com
BTIG maintains buy on Ideaya stock, target at $62 By Investing.com - Investing.com Canada
Items Tagged with 'SHR-4849' - BioWorld Online
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma - GuruFocus.com
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
IDEAYA Secures Global Rights to Promising Cancer Drug SHR-4849 with 73% Response Rate in SCLC Trial - StockTitan
Stifel Financial Corp Cuts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - cnhinews.com
Jane Street Group LLC Trims Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Purchases 118,438 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):